Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 259

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells

Open access
De Luca, Arianna, Fiorillo, Marco, Peiris-Pagès, Maria, Ozsvari, Bela, Smith, Duncan L., Sanchez-Alvarez, Rosa, Martinez-Outschoorn, Ubaldo E., Cappello, Anna Rita, Pezzi, Vincenzo, Lisanti, Michael P., Sotgia, Federica·2015·Oncotarget
DOI 10.18632/oncotarget.4401
Open this paper in CoChat — free account

Abstract

// Arianna De Luca 1,2,3,* , Marco Fiorillo 1,2,3,* , Maria Peiris-Pagès 1,2 , Bela Ozsvari 1,2 , Duncan L. Smith 4 , Rosa Sanchez-Alvarez 1,2 , Ubaldo E. Martinez-Outschoorn 5 , Anna Rita Cappello 3 , Vincenzo Pezzi 3 , Michael P. Lisanti 1,2 and Federica Sotgia 1,2 1 The Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, UK 2 The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, UK 3 Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende (CS), Italy 4 The Cancer Research UK Manchester Institute, University of Manchester, UK 5 The Sidney Kimmel Cancer Center, Philadelphia, PA, USA * These authors contributed equally and should be considered co-first authors Correspondence to: Michael P. Lisanti, email: // Federica Sotgia, email: // Keywords : XCT790, doxycycline, drug repurposing, ERR-α, PGC1-α/β Abbreviations : CSCs, cancer stem-like cells; TICs, tumor-initiating stem-like cells. Received : February 05, 2015 Accepted : May 30, 2015 Published : June 09, 2015 Abstract Here, we show that new mitochondrial biogenesis is required for the anchorage independent survival and propagation of cancer stem-like cells (CSCs). More specifically, we used the drug XCT790 as an investigational tool, as it functions as a specific inhibitor of the ERRα-PGC1 signaling pathway, which governs mitochondrial biogenesis. Interestingly, our results directly demonstrate that XCT790 efficiently blocks both the survival and propagation of tumor initiating stem-like cells (TICs), using the MCF7 cell line as a model system. Mechanistically, we show that XCT790 suppresses the activity of several independent signaling pathways that are normally required for the survival of CSCs, such as Sonic hedgehog, TGFβ-SMAD, STAT3, and Wnt signaling. We also show that XCT790 markedly reduces oxidative mitochondrial metabolism (OXPHOS) and that XCT790-mediated inhibition of CSC propagation can be prevented or reversed by Acetyl-L-Carnitine (ALCAR), a mitochondrial fuel. Consistent with our findings, over-expression of ERRα significantly enhances the efficiency of mammosphere formation, which can be blocked by treatment with mitochondrial inhibitors. Similarly, mammosphere formation augmented by FOXM1, a downstream target of Wnt/β-catenin signaling, can also be blocked by treatment with three different classes of mitochondrial inhibitors (XCT790, oligomycin A, or doxycycline). In this context, our unbiased proteomics analysis reveals that FOXM1 drives the expression of >90 protein targets associated with mitochondrial biogenesis, glycolysis, the EMT and protein synthesis in MCF7 cells, processes which are characteristic of an anabolic CSC phenotype. Finally, doxycycline is an FDA-approved antibiotic, which is very well-tolerated in patients. As such, doxycycline could be re-purposed clinically as a ‘safe’ mitochondrial inhibitor, to target FOXM1 and mitochondrial biogenesis in CSCs, to prevent tumor recurrence and distant metastasis, thereby avoiding patient relapse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4401

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

See all 259

Metadata

Authors
De Luca, A., Fiorillo, M., Peiris-Pagès, M., Ozsvari, B., Smith, D. L., Sanchez-Alvarez, R., Martinez-Outschoorn, U. E., Cappello, A. R., Pezzi, V., Lisanti, M. P., & Sotgia, F.
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2015-06-09
Volume
6
Issue
17
Pages
14777-14795
ISSN
1949-2553 (ISSN-L)
DOI
10.18632/oncotarget.4401
OpenAlex
W1897724420
Cited by
259
References
47
FWCI
7.46
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.